Status:

COMPLETED

Effect and Tolerance of a Probiotic-based Medical Device Administered to Patients With Irritable Bowel Syndrome

Lead Sponsor:

PiLeJe

Conditions:

Irritable Bowel Syndrome

Eligibility:

All Genders

18+ years

Brief Summary

This is an observational, open, longitudinal, multicentre study conducted in France. The study plans to enrol 119 patients with irritable bowel syndrome who will be included by about 50 general pract...

Detailed Description

The study is designed as an observational post-market follow-up study, to confirm the performance of the medical device in real life conditions and document its safety profile. The eligible populatio...

Eligibility Criteria

Inclusion

  • Adult (age ≥ 18 years)
  • Suffering from IBS (Rome IV criteria), whatever the predominant stool pattern, i.e recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with 2 or more of the following criteria: Related to defecation; Associated with a change in frequency of stool; Associated with a change in form (appearance) of stool; with symptom onset at least 6 months before diagnosis;
  • Having access to electronic tools (computer, tablet…) and an internet connection, allowing him to complete the online self-questionnaire.

Exclusion

  • Presence of clinical signs of alarm such as rectorrhagia, fever or recent unexpected weight loss or patient with suspicion or evidence of diseases that exclude IBS diagnosis: including but not limited to inflammatory gastrointestinal disease (e.g. Crohn's disease, ulcerative colitis), colorectal cancer, celiac disease, hyperthyroidism, intestinal infection, lactose intolerance, other malabsorption syndromes (e.g.: fructose), bile acid malabsorption;
  • History of abdominal surgery except appendectomy;
  • Allergy or hypersensitivity to one of the ingredients of the medical device;
  • Inability to fill self-questionnaires or to understand the information notice (cognitive or linguistic issues);
  • Participation to another clinical study or in the exclusion phase of a previous clinical study;
  • Refusal to participate.

Key Trial Info

Start Date :

July 30 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 26 2020

Estimated Enrollment :

119 Patients enrolled

Trial Details

Trial ID

NCT04324658

Start Date

July 30 2019

End Date

June 26 2020

Last Update

September 29 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

General practitioners or gastroenterologists consulting in french private offices

Paris, France